NexGel Inc (NXGL)
NASDAQ:NXGL
Want to see NXGL full AI Analyst Report?
Top Page
NexGel Inc
(NASDAQ:NXGL)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.55
▼(-66.52% Downside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by weak financial quality (persistent losses, negative cash flow, and rising leverage) and bearish technical positioning (below major moving averages with negative MACD). Positive offsets come from earnings-call guidance around the BioNX acquisition potentially tripling revenue and improving profitability, but near-term liquidity and execution risks keep the overall rating low.
Positive Factors
Accretive acquisition expands commercial footprint
The BioNX acquisition brings six commercial-stage regenerative products and an installed base in ~500 U.S. hospitals, giving NexGel immediate recurring revenue channels, clinical validation, and distribution reach. This materially strengthens the company's healthcare revenue base and reduces single-product concentration risk.
Negative Factors
Weak cash generation and limited runway
Persistent negative operating and free cash flow (~-$1.4M TTM) means NexGel cannot self-fund growth and integration costs. The business remains reliant on external financings to cover working capital and acquisition-related spend, elevating dilution and execution risk if revenue ramp or financings slow.
Read all positive and negative factors
Positive Factors
Negative Factors
Accretive acquisition expands commercial footprint
The BioNX acquisition brings six commercial-stage regenerative products and an installed base in ~500 U.S. hospitals, giving NexGel immediate recurring revenue channels, clinical validation, and distribution reach. This materially strengthens the company's healthcare revenue base and reduces single-product concentration risk.
Read all positive factors
NexGel Inc (NXGL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.68M
Dividend YieldN/A
Average Volume (3M)50.95K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth10.14%
EPS Growth12.18%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.40
Shares Outstanding9,225,242
10 Day Avg. Volume60,354
30 Day Avg. Volume50,949
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.84
Price to Sales (P/S)1.11
P/FCF Ratio-9.17
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit2.22
Enterprise Value/Ebitda-4.35
Forecast
1Y Price Target
$2.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.37
Revenue Forecast (FY)$24.06M
NexGel Inc Business Overview & Revenue Model
Company Description
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse produ...
How the Company Makes Money
NexGel makes money primarily by manufacturing and selling hydrogel-based products and by providing contract development and manufacturing services centered on its hydrogel technology. Key revenue streams include: (1) Product sales of hydrogel-base...
NexGel Inc Earnings Call Summary
Earnings Call Date:May 15, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Positive
The call emphasized a transformational acquisition (BioNX), strategic financing and partnership with Sequence LifeScience, strengthened leadership, a commercial product portfolio in ~500 hospitals, and pro forma projections to triple revenue to ~$35M and be accretive — all significant positives. Offsetting these are near‑term operational and liquidity pressures: Q1 revenue declined ~5.7% YoY, cash on hand fell to $1.8M, SG&A is elevated, and some legacy consumer products and key customer relationships have underperformed. Management reported early signs of recovery and initial BioNX sales beginning in Q2, but timing and execution risk remain notable.Positive Updates
Strategic Acquisition of BioNX Closed
Acquisition of BioNX closed in mid‑April; BioNX adds 6 commercial regenerative biomaterial products, positioning the company in a fast‑growing healthcare segment and providing an expanded commercial footprint.
Negative Updates
Quarterly Revenue Decline
Q1 revenue was $2.65 million versus $2.81 million in the prior year period — a year‑over‑year decline of approximately 5.7%, described by management as 'relatively flat' but down overall.
Read all updates
Q1-2026 Updates
Positive
Negative
Strategic Acquisition of BioNX Closed
Acquisition of BioNX closed in mid‑April; BioNX adds 6 commercial regenerative biomaterial products, positioning the company in a fast‑growing healthcare segment and providing an expanded commercial footprint.
Read all positive updates
Company Guidance
The company guided that the BioNX acquisition is expected to be transformative: on a pro forma basis it should approximately triple annual revenue to roughly $35 million and be “immediately accretive to profitability” upon closing; BioNX revenue will begin to be recognized for about half of Q2. Key near‑term financials and capital metrics cited were Q1 revenue of $2.65M (vs. $2.81M year‑ago), cash and restricted cash of ~$2.1M as of 3/31/2026 with $1.8M on hand today, and $13.8M total capital raised (comprised of $8.8M cash and a $5.0M convertible note to Cellularity), while Sequence LifeScience led financing with a $5.5M investment. Operational and pipeline metrics included a BioNX portfolio of 6 commercial regenerative products already approved in ~500 U.S. hospitals, three 510(k) devices in development representing about $4.6M of invested paid‑in capital targeted for commercialization in 2027, 2026 and (as stated) 2020, and an incremental operating run‑rate of roughly $500K per month (salaries, marketing, commissions) for the expanded commercial/R&D footprint.NexGel Inc Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
41
Neutral
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.42M | 8.69M | 4.09M | 2.05M | 1.55M |
| Gross Profit | 4.51M | 2.75M | 374.00K | 256.00K | 8.00K |
| EBITDA | -2.12M | -2.90M | -2.73M | -3.11M | -2.17M |
| Net Income | -3.00M | -3.28M | -3.16M | -4.75M | -4.31M |
Balance Sheet | |||||
| Total Assets | 10.46M | 10.98M | 9.96M | 10.36M | 16.98M |
| Cash, Cash Equivalents and Short-Term Investments | 317.00K | 1.81M | 2.70M | 6.61M | 13.35M |
| Total Debt | 3.09M | 2.83M | 2.80M | 2.08M | 4.26M |
| Total Liabilities | 5.57M | 4.90M | 4.79M | 2.72M | 4.90M |
| Stockholders Equity | 4.46M | 5.75M | 4.70M | 7.64M | 12.09M |
Cash Flow | |||||
| Free Cash Flow | -1.38M | -4.31M | -3.93M | -3.09M | -3.02M |
| Operating Cash Flow | -1.31M | -3.87M | -3.24M | -2.99M | -2.75M |
| Investing Cash Flow | -68.00K | -775.00K | 4.46M | -5.59M | -269.00K |
| Financing Cash Flow | 630.00K | 3.75M | 379.00K | -3.66M | 16.34M |
NexGel Inc Technical Analysis
Negative
1.64
Price Trends
0.59
Negative
0.81
Negative
1.44
Negative
Market Momentum
>-0.01
Negative
48.72
Neutral
24.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NXGL, the sentiment is Negative. The current price of 1.64 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.59, and above the 200-day MA of 1.44, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.72 is Neutral, neither overbought nor oversold. The STOCH value of 24.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NXGL.
NexGel Inc Risk Analysis
NexGel Inc disclosed 29 risk factors in its most recent earnings report. NexGel Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NexGel Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $62.60M | -9.05 | -37.47% | ― | 64.18% | 28.90% | |
53 Neutral | $201.79M | -5.71 | -246.44% | ― | 17.41% | -189.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $32.84M | -6.67 | -166.28% | ― | 3.37% | 15.78% | |
46 Neutral | $20.06M | -3.19 | -8.13% | ― | 10.08% | 71.71% | |
45 Neutral | $12.20M | -1.09 | -258.08% | ― | 39.88% | 64.70% | |
44 Neutral | $6.68M | -1.44 | -55.33% | ― | 10.14% | 12.18% |
* Healthcare Sector Average
NXGL
NexGel Inc
0.57
-1.79
-76.02%
RVP
Retractable Technologies
0.67
0.02
3.08%
MLSS
Milestone Scientific
0.37
-0.43
-53.57%
POCI
Precision Optics Corporation
5.72
1.08
23.28%
SMTI
Sanara MedTech
22.02
-5.80
-20.85%
FEMY
Femasys
4.04
-13.98
-77.58%
NexGel Inc Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
NexGel Updates Investor Presentation Under Regulation FD Disclosure
Neutral
Jun 17, 2026
On June 17, 2026, NexGel, Inc. began using a new investor presentation, signaling an updated package of materials for communicating with current and prospective shareholders. The company characterized the presentation and related disclosure as bei...
Business Operations and StrategyPrivate Placements and Financing
NexGel Raises Insider-Funded Convertible Notes to Bolster Liquidity
Positive
May 15, 2026
Between May 11 and May 14, 2026, NexGel, Inc. raised $1.21 million in a private placement of unsecured convertible promissory notes and accompanying warrants to accredited investors, with the securities convertible at $0.60 per share and warrants ...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
NEXGEL Strengthens Board with Sequence LifeScience Leaders
Positive
May 12, 2026
On May 6, 2026, NEXGEL, Inc. appointed Brian J. Kieser, CEO of Sequence LifeScience, and Kevin Harris, Sequence’s COO, to its board of directors for a term expiring at the next annual shareholder meeting or until successors are elected, unde...
Business Operations and StrategyExecutive/Board Changes
NexGel Appoints Ian Blackman as New Chief Financial Officer
Positive
Apr 30, 2026
On April 27, 2026, NEXGEL’s board appointed veteran finance executive Ian Blackman as Chief Financial Officer, succeeding interim CFO Adam E. Drapczuk III, who will continue as a financial consultant. Blackman’s compensation package in...
Delistings and Listing ChangesRegulatory Filings and Compliance
NexGel Receives Nasdaq Deficiency Notice Over Bid Price
Negative
Apr 24, 2026
On April 22, 2026, NexGel, Inc. disclosed that it received a deficiency notice from Nasdaq after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, triggering noncompliance with Nasdaq Listing Rule 5550(a)(...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
NEXGEL Secures Strategic Financing and Regenerative Portfolio License
Positive
Apr 21, 2026
On April 17, 2026, NEXGEL completed an amended asset purchase and exclusive license deal with Celularity to acquire an exclusive license to a commercial-stage regenerative biomaterials portfolio, related assets and sales representative obligations...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.